Lyon, Jan 13, 2022 – THERANEXUS publishes its cash position as of 31 december 2021. Implementation of a new equity line. DOWNLOAD THERANEXUS press release
Paris, May 21, 2021 – CIBOX announces the establishment of a financing line for a maximum amount of € 1.5 million to initiate the acceleration of development in electric mobility DOWNLOAD CIBOX press release
Paris, May 21, 2021 – BOOSTHEAT announces new funding in the form of an Equity Line with IRIS, up to €10 million, renewable twice DOWNLOAD Boostheat press release
Paris, March 22, 2021 – Hybrigenics has prioritized funding proposed by the company IRIS solution that offers very attractive financial conditions, including the absence of commission and complete flexibility with the ability to terminate without charge to print at any time. These funds will allow, like a SPAC1, to seize…
Lyon, 18 January 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurologicaldiseases and pioneer in the development of drug candidates modulating the interaction between neurons and glialcells, presents an update on its activities and announces the strengthening of its financial visibilityfor the medium term.
Cerinnov Group (code ISIN : FR0013178712 – mnémo : ALPCV), spécialiste de l’ingénierie robotique et des équipements industriels pour l’industrie de la céramique et du verre en France et à l’international, annonce ce jour la mise en place d’un financement en fonds propres d’un montant nominal maximum de 2…
Polyphor AG (SIX: POLN) today announced that it has entered into an equity-inked financing arrangement with the French company IRIS to raise a gross amount of up to CHF 19.3 million over the period of two years. IRIS will receive Polyphor shares to be created from the Company’s conditional…
THERANEXUS ANNOUNCES ITS CASH POSITION AS OF 30 JUNE 2020 ANDIMPLEMENTATION OF A MANDATORY CONVERTIBLE BOND FACILITY • Pro forma cash of €13.3 M at 30 June 2020• Implementation of financing for a maximum total of €4.2 million over 12 months through the issuance of warrants to subscribe mandatory convertible…
Gosselies, Belgium, 29 April 2020, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that it secured EUR 11.0 million financing. The financing will be used to advance both of its key…
We use cookies to optimize our website and our service.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.